Cervical ripening in women with previous cesarean deliveries.
OBJECTIVE
To evaluate the safety and efficacy of preinduction cervical ripening in women with previous cesarean deliveries undergoing induction of labor.


METHODS
Retrospective study of women with previous low transverse cesarean deliveries who underwent ripening of an unfavorable cervix prior to induction of labor (n = 89). Multiparas without previous cesarean deliveries undergoing ripening and induction of labor during the same time period were used for comparison (n = 61). Ripening was performed with prostaglandin E2 (PGE2) gel, or an osmotic dilator, or both. Induction of labor with oxytocin followed the American College of Obstetricians and Gynecologists' guidelines. Outcome data were analyzed using the unpaired Student's t-test or chi 2-test as appropriate. Significance was established at P < 0.05.


RESULTS
The mean gestational age was 39.6 +/- 2.6 and 38.2 +/- 2.9 weeks for the study and comparison groups, respectively. There were no differences between the groups in Bishop score, duration of the first stage of labor, maximum dose of oxytocin, indications for cesarean delivery, puerperal morbidity, birthweight, Apgar scores or NICU admissions. Sixty-four percent (57 of 89) of study women delivered vaginally compared with 82% (50 of 61) of women in the comparison group (P < 0.03). The data were analyzed separately for those women undergoing cervical ripening with PGE2 gel only. No differences were observed between the groups in any of the categories mentioned above.


CONCLUSIONS
Cervical ripening appears to be safe and effective in women with previous low transverse cesarean deliveries undergoing induction of labor with an unfavorable cervix.
Del Valle
G O
GO
Department of Obstetrics and Gynecology, University of Florida Health Science Center, Jacksonville 32209-6511.
Adair
C D
CD
Sanchez-Ramos
L
L
Gaudier
F L
FL
McDyer
D C
DC
Delke
I
I
D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects / Q000502:physiology*; D004106:Dilatation / Q000295:instrumentation; D015232:Dinoprostone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007751:Labor, Induced; D010121:Oxytocin; D010298:Parity; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D016064:Vaginal Birth after Cesarean
D010121:Oxytocin; D015232:Dinoprostone